chromazonarol has been researched along with albaconol in 1 studies
| Studies (chromazonarol) | Trials (chromazonarol) | Recent Studies (post-2010) (chromazonarol) | Studies (albaconol) | Trials (albaconol) | Recent Studies (post-2010) (albaconol) |
|---|---|---|---|---|---|
| 7 | 0 | 2 | 6 | 0 | 1 |
| Protein | Taxonomy | chromazonarol (IC50) | albaconol (IC50) |
|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, N; Kong, W; Li, S; Song, B; Wang, X | 1 |
1 other study(ies) available for chromazonarol and albaconol
| Article | Year |
|---|---|
Facile and divergent optimization of chromazonarol enabled the identification of simplified drimane meroterpenoids as novel pharmaceutical leads.
Topics: Antifungal Agents; Ascomycota; Dose-Response Relationship, Drug; Fusarium; Humans; Microbial Sensitivity Tests; Molecular Structure; Rhizoctonia; Stereoisomerism; Structure-Activity Relationship; Xanthenes | 2022 |